Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDX Celldex Therapeutics	$19.49 -1.8%	$18.87	$14.40 ▼ $47.00	$1.29B	1.39	909,231 shs	923,822 shs
FOLD Amicus Therapeutics	$6.11 -1.6%	$6.83	$5.81 ▼ $12.65	$1.88B	0.64	2.88 million shs	3.29 million shs
LGND Ligand Pharmaceuticals	$103.17 +2.2%	$104.67	$77.43 ▼ $129.90	$1.99B	0.87	116,070 shs	164,245 shs
RGLS Regulus Therapeutics	$7.93 -0.1%	$4.71	$0.83 ▼ $8.20	$549.03M	0.49	903,831 shs	1.00 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDX Celldex Therapeutics	0.00%	-4.23%	-5.66%	+0.72%	-41.47%
FOLD Amicus Therapeutics	0.00%	-1.77%	-8.40%	-33.08%	-37.65%
LGND Ligand Pharmaceuticals	0.00%	+1.55%	-5.69%	-8.03%	+21.31%
RGLS Regulus Therapeutics	0.00%	+0.51%	+1.02%	+529.37%	+246.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDX Celldex Therapeutics	1.9331 of 5 stars	4.5	0.0	0.0	3.4	0.0	0.0
FOLD Amicus Therapeutics	4.0605 of 5 stars	3.4	1.0	4.3	3.6	0.0	1.9
LGND Ligand Pharmaceuticals	4.782 of 5 stars	3.5	3.0	4.4	3.7	3.3	1.9
RGLS Regulus Therapeutics	1.7055 of 5 stars	2.1	5.0	0.0	2.8	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDX Celldex Therapeutics	2.90	Moderate Buy	$53.90	176.55% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	165.50% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$146.14	41.65% Upside
RGLS Regulus Therapeutics	2.29	Hold	$8.50	7.19% Upside

Current Analyst Ratings Breakdown

Latest RGLS, LGND, FOLD, and CLDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	CLDX Celldex Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$44.00 ➝ $38.00
5/9/2025	CLDX Celldex Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$36.00 ➝ $31.00
5/9/2025	CLDX Celldex Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$46.00 ➝ $43.00
5/9/2025	LGND Ligand Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$142.00 ➝ $145.00
5/6/2025	CLDX Celldex Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/2/2025	FOLD Amicus Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $22.00
5/2/2025	FOLD Amicus Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $9.00
5/1/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$9.00
4/30/2025	RGLS Regulus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/30/2025	RGLS Regulus Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$7.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDX Celldex Therapeutics	$7.56M	171.16	N/A	N/A	$9.08 per share	2.15
FOLD Amicus Therapeutics	$543.14M	3.46	N/A	N/A	$0.63 per share	9.70
LGND Ligand Pharmaceuticals	$181.49M	10.97	$4.23 per share	24.39	$40.39 per share	2.55
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	$1.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDX Celldex Therapeutics	-$141.43M	-$2.70	N/A	N/A	N/A	-1,544.32%	-19.75%	-18.86%	8/14/2025 (Estimated)
FOLD Amicus Therapeutics	-$151.58M	-$0.09	N/A	14.21	1.51	-10.62%	12.44%	2.60%	8/14/2025 (Estimated)
LGND Ligand Pharmaceuticals	$52.15M	-$7.12	41.10	27.81	N/A	29.68%	4.95%	4.39%	8/5/2025 (Estimated)
RGLS Regulus Therapeutics	-$30.04M	-$0.73	N/A	N/A	N/A	N/A	-53.07%	-48.58%	8/14/2025 (Estimated)

Latest RGLS, LGND, FOLD, and CLDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CLDX Celldex Therapeutics	-$0.75	-$0.81	-$0.06	-$0.81	$1.08 million	$0.70 million
5/8/2025	Q1 2025	LGND Ligand Pharmaceuticals	$1.23	$1.33	+$0.10	-$2.21	$37.84 million	$45.33 million
5/8/2025	Q1 2025	RGLS Regulus Therapeutics	-$0.29	-$0.15	+$0.14	-$0.15	N/A	N/A
3/20/2025	Q4 2024	RGLS Regulus Therapeutics	-$0.20	-$0.20	N/A	-$0.20	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGLS Regulus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDX Celldex Therapeutics	N/A	24.27	24.27
FOLD Amicus Therapeutics	2.01	3.39	2.42
LGND Ligand Pharmaceuticals	N/A	12.49	11.81
RGLS Regulus Therapeutics	N/A	14.15	14.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDX Celldex Therapeutics	N/A
FOLD Amicus Therapeutics	N/A
LGND Ligand Pharmaceuticals	91.28%
RGLS Regulus Therapeutics	92.38%

Insider Ownership

Company	Insider Ownership
CLDX Celldex Therapeutics	3.80%
FOLD Amicus Therapeutics	2.20%
LGND Ligand Pharmaceuticals	5.90%
RGLS Regulus Therapeutics	4.35%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDX Celldex Therapeutics	150	66.38 million	63.82 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	292.23 million	Optionable
LGND Ligand Pharmaceuticals	80	19.29 million	17.78 million	Optionable
RGLS Regulus Therapeutics	30	69.23 million	62.65 million	Optionable

RGLS, LGND, FOLD, and CLDX Headlines

Recent News About These Companies

Millennium Management LLC Raises Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

June 1 at 3:44 AM | marketbeat.com

Northern Trust Corp Sells 40,071 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

June 1 at 3:18 AM | marketbeat.com

Novartis commences tender offer to acquire Regulus Therapeutics

May 29, 2025 | pharmabiz.com

Novartis emerged victorious in multi-month pursuit of Regulus and potential kidney blockbuster, filing shows

May 29, 2025 | fiercepharma.com

Novartis arm commences tender offer to buy Regulus Therapeutics

May 28, 2025 | medicaldialogues.in

Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) PT at $8.50

May 28, 2025 | americanbankingnews.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Receives Consensus Recommendation of "Hold" from Brokerages

May 26, 2025 | marketbeat.com

Velan Capital Investment Management LP Makes New Investment in Regulus Therapeutics Inc. (NASDAQ:RGLS)

May 22, 2025 | marketbeat.com

Price T Rowe Associates Inc. MD Has $47,000 Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

May 21, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Earns Sell Rating from Analysts at StockNews.com

May 20, 2025 | marketbeat.com

Latham and Covington Advise on Novartis’s Acquisition of Regulus

May 16, 2025 | lawstreetmedia.com

Octagon Capital Advisors LP Acquires 585,101 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

May 15, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Now Covered by StockNews.com

May 12, 2025 | marketbeat.com

Regulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 9, 2025 | finanznachrichten.de

Regulus Therapeutics Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025 | prnewswire.com

What is Leerink Partnrs' Estimate for RGLS Q1 Earnings?

May 6, 2025 | marketbeat.com

JPMorgan Chase & Co. Purchases 111,485 Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS)

May 5, 2025 | marketbeat.com

REGULUS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Regulus Therapeutics Inc. - RGLS

May 4, 2025 | businesswire.com

Novartis (NVS) To Acquire Regulus Therapeutics in $0.8 Billion Deal

May 4, 2025 | gurufocus.com

Regulus Therapeutics Inc. (NASDAQ:RGLS) Sees Large Decline in Short Interest

May 4, 2025 | marketbeat.com

Regulus Therapeutics (NASDAQ:RGLS) Lowered to "Hold" Rating by Wells Fargo & Company

May 4, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGLS, LGND, FOLD, and CLDX Company Descriptions

Celldex Therapeutics NASDAQ:CLDX

$19.49 -0.35 (-1.76%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$19.78 +0.29 (+1.49%)

As of 07:48 AM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Amicus Therapeutics NASDAQ:FOLD

$6.11 -0.10 (-1.61%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$6.19 +0.08 (+1.29%)

As of 08:09 AM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Ligand Pharmaceuticals NASDAQ:LGND

$103.17 +2.26 (+2.24%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$102.19 -0.98 (-0.95%)

As of 07:48 AM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Regulus Therapeutics NASDAQ:RGLS

$7.93 -0.01 (-0.13%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.93 0.00 (0.00%)

As of 08:19 AM Eastern

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time